Skip to main content
Erschienen in: Current Treatment Options in Gastroenterology 3/2016

07.07.2016 | Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)

Management of Inflammatory Bowel Disease in the Elderly

verfasst von: Elizabeth S. John, MD, Kristina Katz, MD, Mark Saxena, MD, Sita Chokhavatia, MD, Seymour Katz, MD

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Opinion Statement

A substantial and growing proportion of patients with inflammatory bowel disease (IBD) are elderly, and these patients require tailored treatment strategies. However, significant challenges exist in the management of this population due to the paucity of data. Establishing the initial diagnosis and assessing the etiology of future symptoms and flares can be challenging as several other prevalent diseases can masquerade as IBD, such as ischemic colitis, diverticular disease, and infectious colitis. Important pharmacologic considerations include reduced glomerular filtration rate and drug-drug interactions in the elderly. No drug therapy is absolutely contraindicated in this population; however, special risk and benefit assessments should be made. Older patients are more susceptible to side effects of steroids such as delirium, fractures, and cataracts. Budesonide can be an appropriate alternative for mild to moderate ulcerative colitis (UC) or Crohn’s disease (CD) as it has limited systemic absorption. Pill size and quantity, nephrotoxicity, and difficulty of administration of rectal preparations should be considered with 5-aminosalicylic (5-ASA) therapy. Biologics are very effective, but modestly increase the risk of infection in a susceptible group. Based on their mechanisms, integrin receptor antagonists (e.g., vedolizumab) may reduce these risks. Use of antibiotics for anorectal or fistulizing CD or pouchitis in UC increases the risk of Clostridium difficile infection. Pre-existing comorbidities, functional status, and nutrition are important indicators of surgical outcomes. Morbidity and mortality are increased among IBD patients undergoing surgery, often due to postoperative complications or sepsis. Elderly adults with IBD, particularly UC, have very high rates of venous thromboembolism (VTE). Colonoscopy appears safe, but the optimal surveillance interval has not been well defined. Should the octogenarian, nonagenarian, and centurion undergo colonoscopy? The length of surveillance should likely account for the individual’s overall life expectancy. Specific health maintenance should emphasize administering non-live vaccines to patients on thiopurines or biologics and regular skin exams for those on thiopurines. Smoking cessation is crucial to overall health and response to medical therapy, even among UC patients. This article will review management of IBD in the elderly.
Literatur
1.
Zurück zum Zitat Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519–25.CrossRefPubMed Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519–25.CrossRefPubMed
2.
Zurück zum Zitat Hussain SW, Pardi DS. Inflammatory bowel disease in the elderly. Drugs Aging. 2010;27:617–24.CrossRefPubMed Hussain SW, Pardi DS. Inflammatory bowel disease in the elderly. Drugs Aging. 2010;27:617–24.CrossRefPubMed
3.
Zurück zum Zitat Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46:336–43.CrossRefPubMedPubMedCentral Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46:336–43.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat del Val JH. Old age inflammatory bowel disease onset: a different problem? World J Gastroenterol. 2011;17:2734–9.PubMedPubMedCentral del Val JH. Old age inflammatory bowel disease onset: a different problem? World J Gastroenterol. 2011;17:2734–9.PubMedPubMedCentral
5.
Zurück zum Zitat Loftus CG, Loftus Jr EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–61.CrossRefPubMed Loftus CG, Loftus Jr EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–61.CrossRefPubMed
6.••
Zurück zum Zitat Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis. 2011;5:5–13. This study conducted in Western Hungary investigated the incidence and course of IBD with respect to age. They found that in the 1420 incident patients, the prevalence of IBD in the elderly population was increasing with distinct characteristics of CD and UC in the elderly.CrossRefPubMed Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis. 2011;5:5–13. This study conducted in Western Hungary investigated the incidence and course of IBD with respect to age. They found that in the 1420 incident patients, the prevalence of IBD in the elderly population was increasing with distinct characteristics of CD and UC in the elderly.CrossRefPubMed
7.••
Zurück zum Zitat Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423–32. This French based study specifically looked at elderly-onset IBD, and found that the course of IBD is milder in elderly patients, specifically greater than 60 years of age.CrossRefPubMed Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423–32. This French based study specifically looked at elderly-onset IBD, and found that the course of IBD is milder in elderly patients, specifically greater than 60 years of age.CrossRefPubMed
8.
Zurück zum Zitat Gudsoorkar VS, Abraham B. Inflammatory bowel disease in the elderly: hazards of generalizing the evidence. Pract Gastroenterol. 2015: 26-40. Gudsoorkar VS, Abraham B. Inflammatory bowel disease in the elderly: hazards of generalizing the evidence. Pract Gastroenterol. 2015: 26-40.
9.
Zurück zum Zitat Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroeneterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23.CrossRefPubMed Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroeneterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23.CrossRefPubMed
10.
Zurück zum Zitat Lichenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–83.CrossRef Lichenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–83.CrossRef
11.
Zurück zum Zitat Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol. 2011;106:1889–97.CrossRefPubMed Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol. 2011;106:1889–97.CrossRefPubMed
12.
Zurück zum Zitat Shung DL, Abraham B, Sellin J, Hou JK. Medical and surgical complications of inflammatory bowel disease in the elderly: a systematic review. Dig Dis Sci. 2015;60(5):1132–40.CrossRefPubMed Shung DL, Abraham B, Sellin J, Hou JK. Medical and surgical complications of inflammatory bowel disease in the elderly: a systematic review. Dig Dis Sci. 2015;60(5):1132–40.CrossRefPubMed
13.
Zurück zum Zitat Fordtran JS. Colitis due to C.diff toxins, underdiagnosed, highly virulent, and nosocomial. Proc (Baylor Univ Med Cent). 2006;19(1):3–12. Fordtran JS. Colitis due to C.diff toxins, underdiagnosed, highly virulent, and nosocomial. Proc (Baylor Univ Med Cent). 2006;19(1):3–12.
14.
Zurück zum Zitat Collins CE, Ayturk MD, Flahive JM, et al. Epidemiology and outcomes of community-acquired Clostridium difficile infections in medicare beneficiaries. J Am Coll Surg. 2014;218:1141–7.CrossRefPubMedPubMedCentral Collins CE, Ayturk MD, Flahive JM, et al. Epidemiology and outcomes of community-acquired Clostridium difficile infections in medicare beneficiaries. J Am Coll Surg. 2014;218:1141–7.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145:158–65.CrossRefPubMed Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145:158–65.CrossRefPubMed
16.
Zurück zum Zitat Hadithi M, Cazemier M, Meijer GA, et al. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J Gastroenterol. 2008;14:3183–7.CrossRefPubMedPubMedCentral Hadithi M, Cazemier M, Meijer GA, et al. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J Gastroenterol. 2008;14:3183–7.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76.CrossRefPubMed Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76.CrossRefPubMed
18.
Zurück zum Zitat Taleban S. Challenges in the diagnosis and management of inflammatory bowel disease in the elderly. Curr Treat Options Gastro. 2015;13:275–86.CrossRef Taleban S. Challenges in the diagnosis and management of inflammatory bowel disease in the elderly. Curr Treat Options Gastro. 2015;13:275–86.CrossRef
19.
Zurück zum Zitat Nilsen T, Sundström J, Lind L, et al. Serum calprotectin levels in elderly males and females without bacterial or viral infections. Clin Biochem. 2014;47:1065–8.CrossRefPubMed Nilsen T, Sundström J, Lind L, et al. Serum calprotectin levels in elderly males and females without bacterial or viral infections. Clin Biochem. 2014;47:1065–8.CrossRefPubMed
20.
Zurück zum Zitat Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem. 2010;47:259–63.CrossRefPubMed Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem. 2010;47:259–63.CrossRefPubMed
21.
Zurück zum Zitat Page MJ, Poritz LS, Kunselman SJ, et al. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg. 2002;6:606–13.CrossRefPubMed Page MJ, Poritz LS, Kunselman SJ, et al. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg. 2002;6:606–13.CrossRefPubMed
22.
Zurück zum Zitat Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57(12):3080–91.CrossRefPubMed Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57(12):3080–91.CrossRefPubMed
23.
Zurück zum Zitat Lexicomp Online®, Hudson, Ohio: Lexi-Comp, Inc.; 2015. Lexicomp Online®, Hudson, Ohio: Lexi-Comp, Inc.; 2015.
25.
Zurück zum Zitat Ananthakrishnan AN, Binion D. Treatment of ulcerative colitis in the elderly. Dig Dis. 2009;27:327–34.CrossRefPubMed Ananthakrishnan AN, Binion D. Treatment of ulcerative colitis in the elderly. Dig Dis. 2009;27:327–34.CrossRefPubMed
26.
Zurück zum Zitat Vagianos K, Clara I, Carr R, et al. What are adults with inflammatory nowel disease (IBD) eating? A closer look at the dietary habits of a population-based Canadian IBD cohort. JPEN J Parenter Enteral Nutr. pii 10.1177/0148607114549254 Vagianos K, Clara I, Carr R, et al. What are adults with inflammatory nowel disease (IBD) eating? A closer look at the dietary habits of a population-based Canadian IBD cohort. JPEN J Parenter Enteral Nutr. pii 10.​1177/​0148607114549254​
27.
Zurück zum Zitat Lee J, Allen R, Ashley S. British Dietetic Association evidence-based guidelines for the dietary management of Crohn’s disease in adults. J Hum Nutr Diet. 27(3): 207-18. Lee J, Allen R, Ashley S. British Dietetic Association evidence-based guidelines for the dietary management of Crohn’s disease in adults. J Hum Nutr Diet. 27(3): 207-18.
28.
Zurück zum Zitat Martin GS, Tapsell LC, Denmeade S. Relative validity of a diet history interview in an intervention trial manipulating dietary fat in the management of Type II diabetes mellitus. Prev Med. 36(4): 420-8. Martin GS, Tapsell LC, Denmeade S. Relative validity of a diet history interview in an intervention trial manipulating dietary fat in the management of Type II diabetes mellitus. Prev Med. 36(4): 420-8.
29.
Zurück zum Zitat Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953–61.CrossRefPubMed Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953–61.CrossRefPubMed
30.••
Zurück zum Zitat Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9(6):507–15. This recent review delineates the growing incidence and prevalence of IBD in the elderly, highlights the different pathophysiologies and clinical manifestations between younger and older patients, and reviews the medical and surgical managements of elderly adults with IBD.CrossRefPubMed Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9(6):507–15. This recent review delineates the growing incidence and prevalence of IBD in the elderly, highlights the different pathophysiologies and clinical manifestations between younger and older patients, and reviews the medical and surgical managements of elderly adults with IBD.CrossRefPubMed
31.
Zurück zum Zitat Fangbin Z, Xiang G, Minhu C, et al. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Ther Drug Monit. 2012;34:695–701.CrossRefPubMed Fangbin Z, Xiang G, Minhu C, et al. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Ther Drug Monit. 2012;34:695–701.CrossRefPubMed
32.
Zurück zum Zitat Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893–9.CrossRefPubMed Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893–9.CrossRefPubMed
33.
Zurück zum Zitat Juneja M, Maidoo L, Schwartz MB, Barrie 3rd A, Regueiro M, Dunn M, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.CrossRefPubMed Juneja M, Maidoo L, Schwartz MB, Barrie 3rd A, Regueiro M, Dunn M, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.CrossRefPubMed
34.
Zurück zum Zitat Min H, Montecino-Rodriguez E, Dorshkind K. Effects of aging on early B- and T-cell development. Immunol Rev. 2005;205:7–17.CrossRefPubMed Min H, Montecino-Rodriguez E, Dorshkind K. Effects of aging on early B- and T-cell development. Immunol Rev. 2005;205:7–17.CrossRefPubMed
35.
Zurück zum Zitat D-Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease. Aliment Pharmacol Ther. 1998;129:716–8. D-Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease. Aliment Pharmacol Ther. 1998;129:716–8.
36.
Zurück zum Zitat Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.CrossRefPubMed Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.CrossRefPubMed
37.
Zurück zum Zitat Ramos MI, Allen LH, Mungas DM, et al. Low folate status is associated with impaired cognitive function and dementia in the Sacramento Area Latino Study on Ageing. Am J Clin Nutr. 2005;82:1346–52.PubMed Ramos MI, Allen LH, Mungas DM, et al. Low folate status is associated with impaired cognitive function and dementia in the Sacramento Area Latino Study on Ageing. Am J Clin Nutr. 2005;82:1346–52.PubMed
38.
Zurück zum Zitat Shea B, Swinden MV, Tanjon Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate fur rheumatoid arthritis. J Rheumatol. 2014;109:163–9. Shea B, Swinden MV, Tanjon Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate fur rheumatoid arthritis. J Rheumatol. 2014;109:163–9.
39.
Zurück zum Zitat Bertino J, Cleary J, Ortiz T, Lane A, Supko JG, Ryan D. Cytotoxic agents. Goodman and Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Global Education Holdings; 2011. Bertino J, Cleary J, Ortiz T, Lane A, Supko JG, Ryan D. Cytotoxic agents. Goodman and Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Global Education Holdings; 2011.
40.
Zurück zum Zitat Bannwarth B, Péhourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30(3):194–210.CrossRefPubMed Bannwarth B, Péhourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30(3):194–210.CrossRefPubMed
41.
Zurück zum Zitat Crom WR, Evan WE. Methotrexate. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. New York: Lippincott Williams & Wilkins; 1992. Crom WR, Evan WE. Methotrexate. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. New York: Lippincott Williams & Wilkins; 1992.
42.
Zurück zum Zitat Cudmore J, Seftel M, Sisler J, Zarychanski R. Methotrexate and trimethoprim-sulfamethoxazole toxicity from this combination continues to occur. Can Fam Physician. 2014;60(1):53–6.PubMedPubMedCentral Cudmore J, Seftel M, Sisler J, Zarychanski R. Methotrexate and trimethoprim-sulfamethoxazole toxicity from this combination continues to occur. Can Fam Physician. 2014;60(1):53–6.PubMedPubMedCentral
43.
Zurück zum Zitat Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1416–21.CrossRefPubMed Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1416–21.CrossRefPubMed
44.
Zurück zum Zitat Turrentine FE, Wang H, Simpson VB, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203:865–77.CrossRefPubMed Turrentine FE, Wang H, Simpson VB, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203:865–77.CrossRefPubMed
45.
Zurück zum Zitat Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187–208.CrossRefPubMed Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187–208.CrossRefPubMed
46.
Zurück zum Zitat Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363–9.CrossRefPubMed Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363–9.CrossRefPubMed
47.
Zurück zum Zitat Irving PM, Shanahan F, Rampton DS. Drug interactions in inflammatory bowel disease. Am J Gastroenterol. 2008;103:207–19.CrossRefPubMed Irving PM, Shanahan F, Rampton DS. Drug interactions in inflammatory bowel disease. Am J Gastroenterol. 2008;103:207–19.CrossRefPubMed
48.
Zurück zum Zitat Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013; 145-1007-15. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013; 145-1007-15.
49.
Zurück zum Zitat Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–81.CrossRefPubMedPubMedCentral Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–81.CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Mehmood F, Wysocki J, Serper M, et al. Efficacy and safety of thiopurine therapy in patients with elderly onset ulcerative colitis. Aliment Pharma Ther. 2015. Mehmood F, Wysocki J, Serper M, et al. Efficacy and safety of thiopurine therapy in patients with elderly onset ulcerative colitis. Aliment Pharma Ther. 2015.
51.
Zurück zum Zitat Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–9.CrossRefPubMedPubMedCentral Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–9.CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec Claims Database Study. Inflamm Bowel Dis. 2015. Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec Claims Database Study. Inflamm Bowel Dis. 2015.
53.
Zurück zum Zitat Sokol H, Beaugerie L, Maynadie M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063–71.CrossRefPubMed Sokol H, Beaugerie L, Maynadie M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063–71.CrossRefPubMed
54.
Zurück zum Zitat Jeuring S, Van den Heuvel T, Zeegers M, et al. Is elderly-onset ulcerative colitis a different entity?—natural disease course and treatment response compared to adult-onset disease in the population-based IBD-SL cohort. J Crohns Colitis. 2014;8 Suppl 1:S3–4.CrossRef Jeuring S, Van den Heuvel T, Zeegers M, et al. Is elderly-onset ulcerative colitis a different entity?—natural disease course and treatment response compared to adult-onset disease in the population-based IBD-SL cohort. J Crohns Colitis. 2014;8 Suppl 1:S3–4.CrossRef
55.
Zurück zum Zitat Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2014;109:163–9.CrossRefPubMed Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2014;109:163–9.CrossRefPubMed
56.
Zurück zum Zitat Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease; long-term follow up study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404–10.CrossRefPubMed Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease; long-term follow up study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404–10.CrossRefPubMed
57.
Zurück zum Zitat Pardi DS, Loftus Jr EV, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging. 2002;19(5):355–63.CrossRefPubMed Pardi DS, Loftus Jr EV, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging. 2002;19(5):355–63.CrossRefPubMed
58.
Zurück zum Zitat Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user’s guide. Am J Gastroenterol. 1997;92(9):1424–8.PubMed Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user’s guide. Am J Gastroenterol. 1997;92(9):1424–8.PubMed
59.
Zurück zum Zitat Lobaton T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015. Lobaton T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015.
60.
Zurück zum Zitat Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123–8.CrossRefPubMed Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123–8.CrossRefPubMed
61.
Zurück zum Zitat Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):309–15.CrossRefPubMedPubMedCentral Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):309–15.CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30(3):210–26.CrossRefPubMed Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30(3):210–26.CrossRefPubMed
63.
Zurück zum Zitat Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.CrossRefPubMed Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.CrossRefPubMed
64.
Zurück zum Zitat Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58(4):492–500.CrossRefPubMed Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58(4):492–500.CrossRefPubMed
65.
Zurück zum Zitat Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis. 2012;18:174–9.CrossRefPubMed Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis. 2012;18:174–9.CrossRefPubMed
66.
Zurück zum Zitat Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861–8.CrossRefPubMed Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861–8.CrossRefPubMed
67.
Zurück zum Zitat Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D’Inca R, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.CrossRefPubMed Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D’Inca R, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.CrossRefPubMed
68.
Zurück zum Zitat Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor. Scand J Gastroenterol. 2015;50:312–20.CrossRefPubMed Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor. Scand J Gastroenterol. 2015;50:312–20.CrossRefPubMed
69.
Zurück zum Zitat Kim M, Dam A, Green J. Common GI drug interactions in the elderly. Curr Treat Options Gastroenterol. 2014;12:292–309.CrossRefPubMed Kim M, Dam A, Green J. Common GI drug interactions in the elderly. Curr Treat Options Gastroenterol. 2014;12:292–309.CrossRefPubMed
70.
Zurück zum Zitat Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin N Am. 2014;43(3):525–41.CrossRef Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin N Am. 2014;43(3):525–41.CrossRef
71.
Zurück zum Zitat Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systemic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–904.CrossRefPubMed Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systemic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–904.CrossRefPubMed
72.
Zurück zum Zitat Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT registry. Am J Gastroenterol. 2014;109(2):212–23.CrossRefPubMed Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT registry. Am J Gastroenterol. 2014;109(2):212–23.CrossRefPubMed
73.
Zurück zum Zitat Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.CrossRefPubMedPubMedCentral Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(1):58–64.CrossRefPubMed Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(1):58–64.CrossRefPubMed
75.
Zurück zum Zitat Nyboe A, Pasternak B, Basit S, Andersson M, Svanström H, Caspersen S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311(23):2406–13.CrossRef Nyboe A, Pasternak B, Basit S, Andersson M, Svanström H, Caspersen S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311(23):2406–13.CrossRef
76.
Zurück zum Zitat Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.CrossRefPubMed Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.CrossRefPubMed
77.
Zurück zum Zitat Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. 2004;50(4):1040–50.CrossRefPubMed Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. 2004;50(4):1040–50.CrossRefPubMed
78.
Zurück zum Zitat McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy. 2012;4(9):883–98.CrossRefPubMedPubMedCentral McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy. 2012;4(9):883–98.CrossRefPubMedPubMedCentral
79.
Zurück zum Zitat Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.CrossRefPubMed Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.CrossRefPubMed
80.
Zurück zum Zitat Feagan BG, Rutgerrts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, axler J, Kim HF, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedlizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369-699-710. Feagan BG, Rutgerrts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, axler J, Kim HF, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedlizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369-699-710.
81.
Zurück zum Zitat Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–25.CrossRefPubMed Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–25.CrossRefPubMed
82.
Zurück zum Zitat Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672–83.CrossRefPubMed Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672–83.CrossRefPubMed
83.
Zurück zum Zitat Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab with advancing age in patients with ulcerative colitis: results from the GEMINI I study [poster Sa1274]. Poster presented at: 2015 Digestive Disease Week (DDW); 2015; Washington, DC Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab with advancing age in patients with ulcerative colitis: results from the GEMINI I study [poster Sa1274]. Poster presented at: 2015 Digestive Disease Week (DDW); 2015; Washington, DC
84.
Zurück zum Zitat Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab with advancing age in patients with Crohn’s disease: results from the GEMINI 2 study [poster P1764]. Honolulu: Poster presented at: 2015 American College of Gastroenterology Annual Scientific Meeting; 2015. Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab with advancing age in patients with Crohn’s disease: results from the GEMINI 2 study [poster P1764]. Honolulu: Poster presented at: 2015 American College of Gastroenterology Annual Scientific Meeting; 2015.
85.
Zurück zum Zitat Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27:193–209.CrossRefPubMed Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27:193–209.CrossRefPubMed
86.
Zurück zum Zitat Cios A, Wyska E, Szymura-Oleksiak J, Grodzicki T. Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. Exp Gerontol. 2014;57:107–13.CrossRefPubMed Cios A, Wyska E, Szymura-Oleksiak J, Grodzicki T. Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. Exp Gerontol. 2014;57:107–13.CrossRefPubMed
87.
Zurück zum Zitat Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med. 1978;88:361–2.CrossRefPubMed Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med. 1978;88:361–2.CrossRefPubMed
88.
Zurück zum Zitat Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54:679–708.CrossRefPubMed Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54:679–708.CrossRefPubMed
89.
Zurück zum Zitat Kaplan GG et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680–7.CrossRefPubMed Kaplan GG et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680–7.CrossRefPubMed
90.
Zurück zum Zitat Kaplan GG et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg. 2011;146:959–64.CrossRefPubMed Kaplan GG et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg. 2011;146:959–64.CrossRefPubMed
91.
Zurück zum Zitat Ha C, Payless T, Wick E. Increased incidence of postoperative complications in older inflammatory bowel disease patients having intestinal surgery [abstract 104]. Gastroenterology. 2012;142 Suppl 1:S245. Ha C, Payless T, Wick E. Increased incidence of postoperative complications in older inflammatory bowel disease patients having intestinal surgery [abstract 104]. Gastroenterology. 2012;142 Suppl 1:S245.
92.
Zurück zum Zitat Ha CY, Katz S. Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr Gastroenterology Rep. 2013;15:310.CrossRef Ha CY, Katz S. Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr Gastroenterology Rep. 2013;15:310.CrossRef
93.
Zurück zum Zitat Ikeuchi H, Uchino M, Matsuoka H, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today. 2014;44:39–43.CrossRefPubMed Ikeuchi H, Uchino M, Matsuoka H, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today. 2014;44:39–43.CrossRefPubMed
94.
Zurück zum Zitat Blonski W, Lichenstein GR. Survival in elderly patients with ulcerative colitis and colorectal cancer. Dig Dis Sci. 2012;57:1435–8.CrossRefPubMed Blonski W, Lichenstein GR. Survival in elderly patients with ulcerative colitis and colorectal cancer. Dig Dis Sci. 2012;57:1435–8.CrossRefPubMed
95.
Zurück zum Zitat Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Ailment Pharmacol Ther. 2014;39(5):459–77.CrossRef Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Ailment Pharmacol Ther. 2014;39(5):459–77.CrossRef
96.
Zurück zum Zitat Duricova D, Burisch J, Jess T, Gower-Rousseau CG, Lakatos PL. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohn’s Colitis. 2014;8:1351–61.CrossRef Duricova D, Burisch J, Jess T, Gower-Rousseau CG, Lakatos PL. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohn’s Colitis. 2014;8:1351–61.CrossRef
97.
Zurück zum Zitat Wang YR, Cangemi JR, Loftus Jr EV, Picco MF. Rate of early/missed colorectal cancers after colonoscopy in older paitents with or without inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108:444–9.CrossRefPubMed Wang YR, Cangemi JR, Loftus Jr EV, Picco MF. Rate of early/missed colorectal cancers after colonoscopy in older paitents with or without inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108:444–9.CrossRefPubMed
98.
Zurück zum Zitat Terheggen G, Lanyi B, Schanz S, et al. Safety, feasibility, tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy. 2008;40:656–63.CrossRefPubMed Terheggen G, Lanyi B, Schanz S, et al. Safety, feasibility, tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy. 2008;40:656–63.CrossRefPubMed
99.
Zurück zum Zitat Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150:849–57. W152.CrossRefPubMed Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150:849–57. W152.CrossRefPubMed
100.
Zurück zum Zitat Arora G, Mannalithara A, Singh G, et al. Risk of perforation from a colonoscopy in adults: a large population-based study. Gastrointest Endosc. 2009;69:654–64.CrossRefPubMed Arora G, Mannalithara A, Singh G, et al. Risk of perforation from a colonoscopy in adults: a large population-based study. Gastrointest Endosc. 2009;69:654–64.CrossRefPubMed
101.
Zurück zum Zitat Day LW, Kwon A, Inadomi JM, et al. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc. 2011;74:885–96.CrossRefPubMedPubMedCentral Day LW, Kwon A, Inadomi JM, et al. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc. 2011;74:885–96.CrossRefPubMedPubMedCentral
102.
Zurück zum Zitat Horton HA, Kim H, Melmed GY. Vaccinations in older adults with gastrointestinal diseases. Clin Geriatr Med. 2014;30(1):17–28.CrossRefPubMed Horton HA, Kim H, Melmed GY. Vaccinations in older adults with gastrointestinal diseases. Clin Geriatr Med. 2014;30(1):17–28.CrossRefPubMed
103.
Zurück zum Zitat Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc. 2015;90(7):865–73.CrossRefPubMed Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc. 2015;90(7):865–73.CrossRefPubMed
104.
Zurück zum Zitat Melmed GY, Spiegel BM, Bressler B, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn’s disease: 1 size does not fit all. Clin Gastroenterol Hepatol. 2010;8:655–9.CrossRefPubMed Melmed GY, Spiegel BM, Bressler B, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn’s disease: 1 size does not fit all. Clin Gastroenterol Hepatol. 2010;8:655–9.CrossRefPubMed
105.
Zurück zum Zitat Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterology. 2008;103:2272–80.CrossRef Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterology. 2008;103:2272–80.CrossRef
Metadaten
Titel
Management of Inflammatory Bowel Disease in the Elderly
verfasst von
Elizabeth S. John, MD
Kristina Katz, MD
Mark Saxena, MD
Sita Chokhavatia, MD
Seymour Katz, MD
Publikationsdatum
07.07.2016
Verlag
Springer US
Erschienen in
Current Treatment Options in Gastroenterology / Ausgabe 3/2016
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-016-0099-6

Weitere Artikel der Ausgabe 3/2016

Current Treatment Options in Gastroenterology 3/2016 Zur Ausgabe

Pancreas (T Stevens, Section Editor)

Preventing Post-ERCP Pancreatitis: Update 2016

Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)

Managing Esophageal Dysphagia in the Elderly

Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)

Endoscopy in the Elderly: a Cautionary Approach, When to Stop

Pancreas (T Stevens, Section Editor)

Management of Disconnected Pancreatic Duct Syndrome

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.